Zinc Finger E-box binding Homeobox 1 as Prognostic Biomarker and its Correlation with Infiltrating Immune Cells and Telomerase in Lung Cancer

다국어 초록 (Multilingual Abstract)

The aim of this study was to identify the expression of zinc finger E-box binding homeobox 1 (ZEB1), its prognostic significance, and correlation between ZEB1 and infiltrating immune cells in lung cancer. Correlation between ZEB1 and telomerase was also analyzed in different types of cancers. RNA sequencing analysis and survival rates of patients were confirmed by Gene Expression Profiling Interactive Analysis (GEPIA). The Kaplan-Meier plotter and PrognoScan databases were used to analyze the prognostic value of ZEB1 in various cancers. The Tumor IMmune Estimation Resource (TIMER) was used to determine the correlation between ZEB1 and infiltrating immune cells. Lower ZEB1 expression was lower in lung cancer and was related to poor prognosis in lung adenocarcinoma (LUAD). ZEB1 expression exhibited a significantly positive correlation with infiltration levels of immune cells in LUAD and lung squamous cell carcinoma.
Furthermore, we found that the ZEB1 expression correlated with subunits of telomerase. Our findings suggest ZEB1 as a potential biomarker to be used for prognostic significance and tumor immunology in lung cancer. The correlation between the expression of ZEB1 and telomere-related gene will help in understand the cancer-promoting mechanisms.

참고문헌 (Reference)

1 Sanchez-Tillo E, "beta-catenin/TCF4 complex induces the epithelialto-mesenchymal transition(EMT)-activator ZEB1 to regulate tumor invasiveness" 108 : 19204-19209, 2011

2 Scott CL, "ZEBs : Novel Players in Immune Cell Development and Function" 40 : 431-446, 2019

3 Yu P, "ZEB1 stimulates breast cancer growth by up-regulating hTERT expression" 495 : 2505-2511, 2018

4 Sanchez-Tillo E, "ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatinremodeling protein BRG1" 29 : 3490-3500, 2010

5 Siles L, "ZEB1 imposes a temporary stage-dependent inhibition of muscle gene expression and differentiation via CtBP-mediated transcriptional repression" 33 : 1368-1382, 2013

6 Terashita K, "ZEB1 expression is associated with prognosis of intrahepatic cholangiocarcinoma" 69 : 593-599, 2016

7 Sanchez-Tillo E, "ZEB1 and TCF4 reciprocally modulate their transcriptional activities to regulate Wnt target gene expression" 34 : 5760-5770, 2015

8 Zhang P, "ZEB1 : at the crossroads of epithelialmesenchymal transition, metastasis and therapy resistance" 14 : 481-487, 2015

9 Miyazono K, "Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer" 85 : 314-323, 2009

10 Aigner K, "The transcription factor ZEB1(deltaEF1)promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity" 26 : 6979-6988, 2007

11 Cayuela ML, "The telomerase RNA component Terc is required for the tumour-promoting effects of Tert overexpression" 6 : 268-274, 2005

12 Vandewalle C, "The role of the ZEB family of transcription factors in development and disease" 66 : 773-787, 2009

13 Mooney SM, "The presence of androgen receptor elements regulates ZEB1 expression in the absence of androgen receptor" 116 : 115-123, 2015

14 Moroishi T, "The emerging roles of YAP and TAZ in cancer" 15 : 73-79, 2015

15 Kalluri R, "The basics of epithelial-mesenchymal transition" 119 : 1420-1428, 2009

16 Maitra A, "The RNA component of telomerase as a marker of biologic potential and clinical outcome in childhood neuroblastic tumors" 85 : 741-749, 1999

17 Sahay D, "The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer" 6 : 20604-20620, 2015

18 Wellner U, "The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs" 11 : 1487-1495, 2009

19 Cristofari G, "Telomere length homeostasis requires that telomerase levels are limiting" 25 : 565-574, 2006

20 Shen ZY, "Telomere and telomerase in the initial stage of immortalization of esophageal epithelial cell" 8 : 357-362, 2002

21 Liu Z, "Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells" 32 : 4203-4213, 2013

22 Yashima K, "Telomerase expression in respiratory epithelium during the multistage pathogenesis of lung carcinomas" 57 : 2373-2377, 1997

23 Li T, "TIMER : A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells" 77 : e108-e110, 2017

24 Kerr KM, "Second ESMO consensus conference on lung cancer : pathology and molecular biomarkers for non-small-cell lung cancer" 25 : 1681-1690, 2014

25 Aghdassi A, "Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer" 61 : 439-448, 2012

26 Chen B, "Prognostic value of ZEB-1 in solid tumors : a meta-analysis" 19 : 635-, 2019

27 Bronsert P, "Prognostic significance of Zinc finger E-box binding homeobox 1(ZEB1)expression in cancer cells and cancer-associated fibroblasts in pancreatic head cancer" 156 : 97-108, 2014

28 Mizuno H, "PrognoScan : a new database for meta-analysis of the prognostic value of genes" 2 : 18-, 2009

29 Yang X, "Overexpression of zinc finger E-box binding homeobox factor 1 promotes tumor invasiveness and confers unfavorable prognosis in esophageal squamous cell carcinoma" 35 : 11977-11984, 2014

30 Rhodes DR, "Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles" 9 : 166-180, 2007

31 Goscinski MA, "Nuclear, cytoplasmic, and stromal expression of ZEB1 in squamous and small cell carcinoma of the esophagus" 123 : 1040-1047, 2015

32 Sekido Y, "Molecular genetics of lung cancer" 54 : 73-87, 2003

33 Cagle PT, "Lung cancer biomarkers : present status and future developments" 137 : 1191-1198, 2013

34 Japanese Gastric Cancer Association, "Japanese gastric cancer treatment guidelines 2014 (ver. 4)" 20 : 1-19, 2017

35 Chen B, "JAK1 as a prognostic marker and its correlation with immune infiltrates in breast cancer" 11 : 11124-11135, 2019

36 Kitamura T, "Immune cell promotion of metastasis" 15 : 73-86, 2015

37 Dome JS, "High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms' tumor" 23 : 9138-9145, 2005

38 Zhang GJ, "High expression of ZEB1 correlates with liver metastasis and poor prognosis in colorectal cancer" 5 : 564-568, 2013

39 Hou J, "Gene expressionbased classification of non-small cell lung carcinomas and survival prediction" 5 : e10312-, 2010

40 Tang Z, "GEPIA : a web server for cancer and normal gene expression profiling and interactive analyses" 45 : W98-W102, 2017

41 Li X, "GATA3 acetylation at K119 by CBP inhibits cell migration and invasion in lung adenocarcinoma" 497 : 633-638, 2018

42 Ohtani H, "Focus on TILs : prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer" 7 : 4-, 2007

43 Suzuki K, "Expression of ZEBs in gliomas is associated with invasive properties and histopathological grade" 16 : 1758-1764, 2018

44 Sanchez-Tillo E, "Expanding roles of ZEB factors in tumorigenesis and tumor progression" 1 : 897-912, 2011

45 Murai T, "Epithelial-tomesenchymal transition predicts prognosis in clinical gastric cancer" 109 : 684-689, 2014

46 Chae YK, "Epithelial-mesenchymal transition(EMT)signature is inversely associated with T-cell infiltration in non-small cell lung cancer(NSCLC)" 8 : 2918-, 2018

47 Kurahara H, "Epithelial-mesenchymal transition and mesenchymal-epithelial transition via regulation of ZEB1 and ZEB-2 expression in pancreatic cancer" 105 : 655-661, 2012

48 Tsuji T, "Epithelial-mesenchymal transition and cell cooperativity in metastasis" 69 : 7135-7139, 2009

49 Schmalhofer O, "E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer" 28 : 151-166, 2009

50 Wu DW, "DDX3enhances oncogenic KRASinduced tumor invasion in colorectal cancer via the betacatenin/ZEB1 axis" 7 : 22687-22699, 2016

51 Fujimoto J, "Current concepts on the molecular pathology of non-small cell lung carcinoma" 31 : 306-313, 2014

52 Li B, "Comprehensive analyses of tumor immunity : implications for cancer immunotherapy" 17 : 174-, 2016

53 Zhou YM, "Clinicopathological significance of ZEB1 protein in patients with hepatocellular carcinoma" 19 : 1700-1706, 2012

54 Yao X, "Clinicopathological significance of ZEB-1 and E-cadherin proteins in patients with oral cavity squamous cell carcinoma" 10 : 781-790, 2017

55 Hiyama E, "Clinical utility of telomerase in cancer" 21 : 643-649, 2002

56 Navarro A, "Clinical significance of long non-coding RNA HOTTIP in early-stage non-small-cell lung cancer" 19 : 55-, 2019

57 Okugawa Y, "Clinical significance of Zinc finger E-box Binding homeobox 1(ZEB1)in human gastric cancer" 106 : 280-285, 2012

58 Hashiguchi M, "Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma(HCC)" 13 : 572-, 2013

59 Singh AB, "Claudin-1 up-regulates the repressor ZEB-1 to inhibit Ecadherin expression in colon cancer cells" 41 : 2140-2153, 2011

60 Miranda A, "Cancer stemness, intratumoral heterogeneity, and immune response across cancers" 116 : 9020-9029, 2019

61 Siegel R, "Cancer statistics. 2012" 62 : 10-29, 2012

62 Gu Y, "CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma" 12 : 784-807, 2020

63 Mabey Gilsenan J, "CADRE: the Central Aspergillus Data REpository 2012" 40 : D660-D666, 2012

64 Zeisberg M, "Biomarkers for epithelial-mesenchymal transitions" 119 : 1429-1437, 2009

65 Gyorffy B, "An online survival analysis tool to rapidly assess the effect of 22, 277 genes on breast cancer prognosis using microarray data of 1, 809 patients" 123 : 725-731, 2010

66 Qin Y, "An hTERT/ZEB1 complex directly regulates Ecadherin to promote epithelial-to-mesenchymal transition(EMT)in colorectal cancer" 7 : 351-361, 2016

67 Sato M, "A translational view of the molecular pathogenesis of lung cancer" 2 : 327-343, 2007

68 Block CJ, "A stroma-corrected ZEB1 transcriptional signature is inversely associated with antitumor immune activity in breast cancer" 9 : 17807-, 2019

69 MacMahon B, "A code of ethical conduct for epidemiologists?" 44 : 147S-149S, 1991